Dr. Patrick Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC including analytical development and quality control. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA.
Patrick has been serving on CBA board for several terms since 2003. His roles include directors of membership, activity, and alliance. He successfully organized CBA education seminar "Dragon Parents Summit Talk", and has been working as a committee member for Ho Family Scholarship. Besides CBA board member's duty, Patrick also participated many other activities in the Bay Area. He helped organize a big literature seminar for Sichuan earthquake fundraising, led local student math team and science bowl teams, took judge and judge leader roles in Silicon Valley science fair, and served as CABS journal editor "Trends in Bio/Pharmaceutical Industry" for seven years. He is also an active writer with many readers.
Dr. Mark Chen Vice President, Dr. Chen is an immunologist with expertise in antibody design for therapeutic use and new vaccine discovery for the treatment of human
cancers and infectious disease. He completed his Ph.D. in Immunology
from Texas A&M University and has a track record of successful
leadership roles in R&D, business development, and the marketing of
therapeutic antibodies. Dr. Chen has been an active contributing Chinese
BioScience Association board member since 2014. He has
enthusiastically served CBA in the capacities of Secretary (2014, 2015)
and Vice President (2016).
Dr. Huifang Li Vice, Dr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS diseases such as epilepsy, drug addiction, and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations.
Dr. Katherine Wang, Treasurer Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Vivian Fu, Ph.D, CBA Membership Dr. Fu received her Master degree in Immunology from Xi’an Jiaotong University, and Ph.D from Department of Pathology and Cell Biology at the University of South Florida. After graduation, she joined Moffitt Cancer Center as a Postdoc and worked on drug discovery and drug development. In 2013, Dr. Fu joined Bio-Rad as a Data Scientist and built Bio-Rad business intelligence platform and helped R&D, marketing, and sales teams on Business Development strategy, New Product Development, OEM decision, and marketing campaign.
Wenyi Chen, PhD, Alliance, Dr. Chen has been serving on CBA board for several terms since 2015. He helped organizing CBA workshop and annual conference. Wenyi currently works as Field Application Scientist at Nexcelom Bioscience and provides technical consultation in image cytometry, which has been widely used in immuno-oncology, 3D tumorspheroids and drug screening. Before joining Nexcelom in 2016, Wenyi conducted his research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation from human embryonic stem cells (hESCs) and the efficacy of the cell therapy using cardiac cells derived from hESCs. He received his Ph.D. from the Ohio State University and his B.S. from National Taiwan University.
Dr. Michelle Chen, Advisor Dr. Chen is a biotech entrepreneur & executive with extensive experience in biopharma, diagnostics and life sciences. She has a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. Prior to this role, she was involved in the personalized medicine effort for Roche. Dr. Chen started her biotech career in early drug discovery& development at Scios and later Abgenix as a group leader working on the assay development of antibody drugs. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University. She has been a CBA board member, advisor and volunteer in the last five years and a FAST program advisor for BayBio dedicated to help biotech start-ups grow and succeed. She was the president of CBA 2014.
Dr. Lin Sun-Hoffman, Advisor Dr. Sun-Hoffman, Partner at Liu, Zheng, Chen & Hoffman LLP, is a licensed patent attorney and advises on issues related to intellectual property and technology transfer matters. She also consults on biotechnology and pharmaceutical business-related matters. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. She previously worked for Life Technologies/ABI, BIO, Celera Genomics, US Patent and Trademark Office and National Institutes of Health. She is the former president of Chinese Biopharmaceutical Association based in Washington DC, currently serves on board of US China Green Energy Council, a member of Bayhelix. Dr. Sun-Hoffman has a PhD in Biochemistry/Cell and Molecular Biology. She was the president of CBA 2013.
Shian-Jiun (SJ) Shih, Ph.D. Advisor (CBA Founding President) SJ Shih is a consultant serving pharmaceutical and biotechnology clients, with more than twenty years’ of industrial experience and specializing in assay development and biomarkers.
From 2009 to 2015 she worked at the Translational Medicine Research Centre, Merck Research Laboratories, Merck Sharp & Dohme, most recently as the Director and Site Lead of Molecular Biomarkers and Diagnostics. She lead 29 scientists with broad translational research skills, including immunoassays, nucleic acid-based assays and next generation sequencing, mass spectrometry, flow cytometry, cell-based assays, immunohistory chemistry, and bioinformatics. Her group was responsible for developing clinical biomarker assays to support early phase clinical trials, including those for Keytruda, as well as for collaborating with academic leaders in biomarker discovery, and for building primate disease models for target validation studies.
Prior to joining Merck, she was with Cell Genesys, a biotechnology company developing cell-based immunotherapy and oncolytic adenovirus-based gene therapy products from 2001 to 2008. As the Director of Assay Development there, her group developed quality control and clinical monitoring assays for phase 3 clinical trials, and conducted product characterization studies to answer inquires from FDA, and from regulatory authorities from other countries.
During her time at Bayer Pharmaceuticals (2000-2001), SJ successfully developed liquid parenteral formulations and explored several novel drug delivery routes for biological drugs. From 1994 to 2000 she worked at Aventis (currently Sanofi) in various capacities, including characterization and purification of therapeutic monoclonal antibodies, development of a cell isolation medical device for bone marrow transplantation, liquid formulation and enhanced cellular delivery for gene therapy products. She started her industrial career in 1993 at BioSource (currently Invitrogen) and produced antibody reagents for research and in vitro diagnostic use.
SJ received a BS degree in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison, and completed her post-doctoral training at the department of Molecular Pharmacology at Stanford University.